IQ-AI Ltd

  • News & Announcements
  • Shareholder Information
  • Investor Relations
  • Significant Shareholders
  • Publications
  • Home
  • Corporate News & Announcements
  • Archive from category "IQ-AI RNS News & Announcements"
 

Category: IQ-AI RNS News & Announcements

  • 0
IQ-AI
Thursday, 05 May 2022 / Published in IQ-AI RNS News & Announcements

Notice of AGM

RNS Number : 4440K IQ-AI Limited 05 May 2022   5 May 2022   IQ-AI Ltd (“IQ-AI” or the “Company”)   Notice of AGM   IQ-AI Limited announces that notice of the annual general meeting of the Company, to be held at Third Floor, Forum 4, Grenville Street, St Helier, Jersey, JE2 4UF on 30
  • 0
IQ-AI
Tuesday, 03 May 2022 / Published in IQ-AI RNS News & Announcements

IB Broadens Quantitative Mapping

RNS Number : 1476K IQ-AI Limited 03 May 2022   3 May 2022   IQ-AI Ltd (“IQ-AI” or the “Company”)   IB Neuro’s Quantitative Mapping Method Assesses Metastatic Tumors Study Shows DSC MRI Perfusion Distinguishes Tumor from Non-Tumor Tissue Milwaukee – 3 May 2022:  Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, (OTCQB: IQAIF)
  • 0
IQ-AI
Tuesday, 03 May 2022 / Published in IQ-AI RNS News & Announcements

IB Broadens Quantitative Mapping

– Article source
  • 0
IQ-AI
Thursday, 28 April 2022 / Published in IQ-AI RNS News & Announcements

Final Results

RNS Number : 7683J IQ-AI Limited 28 April 2022   28 April 2022 IQ-AI Ltd (“IQ-AI”, the “Company” and, together with its subsidiaries, the “Group”)   Publication of Annual Report   The Board of IQ-AI Ltd are pleased to present announce that the Company’s audited financial statements for the year ended 31 December 2021.  
  • 0
IQ-AI
Thursday, 10 March 2022 / Published in IQ-AI RNS News & Announcements

IQAI’s Sponsored Phase I Clinical Trial is Open

RNS Number : 2319E IQ-AI Limited 09 March 2022   FOR IMMEDIATE RELEASE IQ-AI LIMITED (“IQ-AI” or the “Company”) IQAI’s Sponsored Phase I Clinical Trial is Open   Milwaukee – 9 March 2022:  IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI) is pleased to announce that the sponsored Phase I clinical trial for oral gallium maltolate (GaM) is
  • 0
IQ-AI
Monday, 28 February 2022 / Published in IQ-AI RNS News & Announcements

Total Voting Rights

RNS Number : 0358D IQ-AI Limited 28 February 2022   28 February 2022 IQ-AI Ltd (“IQ-AI” or the “Company”)   Total Voting Rights   In accordance with the Financial Conduct Authority’s Disclosure and Transparency Rules, IQ-AI announces that the Company has 182,621,390 ordinary shares of 1p each in issue, none of which are held in
  • 0
IQ-AI
Tuesday, 08 February 2022 / Published in IQ-AI RNS News & Announcements

Issue of shares to Mayo Clinic

RNS Number : 9343A IQ-AI Limited 08 February 2022   8 February 2022 IQ-AI Ltd (“IQ-AI” or the “Company”)   Issue of shares to Mayo Clinic   Further to the Company’s announcement dated 9 November 2020, IQ-AI announces the allotment of 113,781 ordinary shares of 1p each in IQ-AI (the “New Ordinary Shares”) to Mayo
  • 0
IQ-AI
Tuesday, 04 January 2022 / Published in IQ-AI RNS News & Announcements

Director/PDMR Shareholding

RNS Number : 3367X IQ-AI Limited 04 January 2022   4 January 2022 IQ-AI Ltd (“IQ-AI” or the “Company”)   Director/PDMR Shareholding   IQ-AI announces that Michael Schmainda, Director of IQAI and CEO of Imaging Biometrics, has been granted an option to subscribe for 5,969,792 ordinary shares of 1p each in the Company (“Ordinary Shares”)
  • 0
IQ-AI
Friday, 17 December 2021 / Published in IQ-AI RNS News & Announcements

IQ-AI Prepares for Phase I Clinical Trial Launch

RNS Number : 0182W IQ-AI Limited 17 December 2021   17 December 2021 IQ-AI LIMITED (“IQ-AI” or the “Company”) IQ-AI Prepares for Phase I Clinical Trial Launch IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI), IQ-AI has been working with the clinical team at the Medical College of Wisconsin (MCW) to qualify a new supplier for encapsulating
  • 0
IQ-AI
Monday, 13 December 2021 / Published in IQ-AI RNS News & Announcements

Director’s Interest

RNS Number : 4300V IQ-AI Limited 13 December 2021   13 December 2021 IQ-AI Ltd (“IQ-AI” or the “Company”)   Director’s Interest   IQ-AI has been advised that Trevor Brown, Chief Executive of the Company, no longer has an interest in Free Association Books Limited.  Accordingly, Trevor Brown’s interest in the Company is now 32,203,457
  • 1
  • 2
  • 3
  • 4

Recent Posts

  • Notice of AGM

    RNS Number : 4440K IQ-AI Limited 05 May 2022   ...
  • IB Broadens Quantitative Mapping

    RNS Number : 1476K IQ-AI Limited 03 May 2022   ...
  • IB Broadens Quantitative Mapping

    – Article source...
  • Final Results

    RNS Number : 7683J IQ-AI Limited 28 April 2022 ...
  • IQAI’s Sponsored Phase I Clinical Trial is Open

    RNS Number : 2319E IQ-AI Limited 09 March 2022 ...
Portions copyright © 2010-2022 IQ-AI Ltd. All Rights Reserved.
TOP
Our website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.AcceptReject
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT